CATHERINE O'NEILL: Open Payments
NPI 1407455116 · CONCORD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,435 in 48 payments from 11 companies in 2025. Trend: 2023 $1,758 · 2024 $1,001 · 2025 $1,435
Food & beverage: $1,336Education: $99
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 8 | $289 |
| Regeneron Healthcare Solutions, Inc. | 10 | $242 |
| ARS Pharmaceuticals Operations, Inc. | 6 | $238 |
| AstraZeneca Pharmaceuticals LP | 4 | $199 |
| CSL Behring | 3 | $153 |
| GENZYME CORPORATION | 8 | $148 |
| Novartis Pharmaceuticals Corporation | 4 | $79 |
| Amgen Inc. | 2 | $28 |
| Genentech USA, Inc. | 1 | $22 |
| Optinose US, Inc. | 1 | $18 |
Products named: DUPIXENT, NUCALA, NEFFY, TEZSPIRE, Andembry, AYVAKIT, FASENRA, TRELEGY ELLIPTA.
Industry payments across CA — which companies pay providers there.
